A Pilot Study Investigating the Effect of Atezolizumab Monotherapy and Atezolizumab Plus Cobimetinib on the Tumoral Immunoprofile in Liver Metastases From Colorectal Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib
- Indications Colorectal cancer; Liver metastases
- Focus Pharmacodynamics
- Acronyms ATELIER
- 04 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 19 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.